Kidney Dialysis Centers (U.S.) — NAICS 621492

An investor's primer for a general audience — relevant to both public-market and private investors. Figures are U.S. unless noted. Reported data are historical facts; statements about future rates, demand, or margins are forward-looking judgments. Tickers, prices, and valuation language are confined to the investable-universe and how-to-invest sections.

1. Overview

Kidney dialysis centers are freestanding outpatient clinics that filter the blood of people whose kidneys have failed — a life-sustaining treatment most patients need about three times a week, for years, unless they receive a transplant. Because patients cannot stop, the industry is one of the most predictable recurring-revenue businesses in health care, and one of the most politically exposed: a single government payer, Medicare, sets the price for most of the volume.

Why this matters to an investor: demand is chronic and non-discretionary, the U.S. market is a near-duopoly with high barriers to entry, and roughly a tenth of patients — those with private insurance — generate a disproportionate share of the profit. That mix makes the economics unusually sensitive to reimbursement policy and to who ends up paying the bill.

There are two ways in. Public-market investors have two near-pure plays — DaVita (U.S.-focused) and Fresenius Medical Care (global #1) — plus a ring of device and drug suppliers.[1][2] Private investors reach the same industry through private-equity-owned operators (the #3–#5 chains), nonprofit and hospital-affiliated providers, physician joint ventures, value-based kidney-care companies, and the net-lease real estate the clinics sit on. Note that "private" here does not necessarily mean private equity — nonprofits and physician-owned groups are private in the sense that they are not government-owned.

2. What it is and how it is structured

The North American Industry Classification System (NAICS) code 621492 covers establishments primarily engaged in providing outpatient kidney or renal dialysis services.[7] In practice that means:

• In-center hemodialysis — a machine at the clinic filters the patient's blood (the large majority of treatments).
• Home hemodialysis — the same principle, performed at home.
• Peritoneal dialysis (PD) — uses the lining of the abdomen to filter waste, done at home.
• Home-dialysis training and support provided by a certified dialysis facility.

Adjacent activities classified elsewhere (important for reading the federal data):

• Hospital-based dialysis — inpatient and hospital-outpatient dialysis sits under hospitals (NAICS 622), not here.
• Nephrologists' medical practices — kidney physicians bill under offices of physicians (NAICS 621111).
• Other outpatient-care neighbors in the same family: HMO (health maintenance organization) medical centers (621491), freestanding ambulatory surgical and emergency centers (621493), all other outpatient care centers (621498), and medical laboratories (621511).
• Dialysis machines, dialyzers, and PD solution manufacturing — the "picks-and-shovels" layer sits in manufacturing codes such as 334510 (electromedical apparatus, e.g., dialysis machines) and 325412 (pharmaceutical/solution manufacturing).[7]

Ownership mix. The industry is overwhelmingly for-profit and corporate, but not exclusively. Within the Medicare-certified universe, the Medicare Payment Advisory Commission (MedPAC) reported that in 2024, 90% of facilities were for-profit and 10% nonprofit; 96% were freestanding and 4% hospital-based. Two large dialysis organizations — DaVita and Fresenius Medical Care — accounted for 74% of facilities and 75% of dialysis stations.[3] Behind them sit a private-equity-backed #3 (U.S. Renal Care), regional and nonprofit operators (Dialysis Clinic, Inc.; Satellite Healthcare), and physician-partnered joint ventures. Most clinics run on a joint-venture-with-doctors model, because the referring nephrologist is the source of patients.

3. How big it is

Federal ground-truth figures for NAICS 621492:

The market-concentration index (Herfindahl-Hirschman Index, HHI) is suppressed in the federal release, so we do not state one.[5] The receipts and concentration figures are from 2022 while employment and payroll are from 2023, so they are not perfectly comparable and should not be used to derive current revenue per center.

The one number that tells the whole story: about 516 firms operate more than 8,400 establishments, and just four of them collect 88% of the revenue.[4][5] That is one of the most concentrated industries in the entire NAICS system.

Undercount and miscount caveats. Freestanding dialysis is well captured by federal business statistics — it is private, corporate, and consolidated — but three things matter. First, hospital-based dialysis lives in the hospital code (622), so 621492 measures only the freestanding channel (which is the large majority of treatments); that activity is better tracked through Medicare facility data than NAICS statistics.[3][8] Second, County Business Patterns excludes self-employed people, businesses without an employer identification number, nonemployer businesses, and most government workers, so it undercounts the full care-delivery universe.[8] Third, "516 firms" is a concentration signal, not a location count — it understates sites because two firms each run thousands of clinics. Operationally, MedPAC counted 7,605 dialysis facilities and 137,195 stations in 2024 (average 18 stations per facility), and CMS expects to pay about 7,600 facilities in 2026;[3][10] the CBP establishment count (8,418) runs higher because it includes administrative and non-treating sites and reflects a different year.

The patient base: more than 808,000 Americans live with end-stage kidney disease (ESKD), also called end-stage renal disease (ESRD); about 68% are on dialysis and 32% have a functioning transplant.[9]

4. The investable universe

Almost all listed operating exposure runs through two names, with a ring of suppliers and disruptors around them.

Public — the two near-pure plays

Neither company is a clean statistical match for NAICS 621492: DaVita bundles in integrated kidney-care operations, and Fresenius carries substantial medical-technology and pharmaceutical businesses.[1][2]

Public — picks-and-shovels and disruptors

Private and other owners

• U.S. Renal Care — private (PE-backed); the #3 operator, with more than 500 centers across 32 states (roughly 36,000 patients). Its disclosed investor group has included Bain Capital, Summit Partners, Revelstoke Capital Partners, management, and founder Mark Caputo.[25]
• Innovative Renal Care (IRC) — private; more than 230 centers in 28 states serving 16,000+ patients. IRC acquired American Renal Associates in a 2021 transaction sponsored by Nautic Partners.[26]
• Dialysis Clinic, Inc. (DCI) — the largest nonprofit; more than 240 locations and about 14,000 patients.[27]
• Satellite Healthcare — nonprofit; more than 80 centers nationwide.[28]
• Vantive — Baxter's former kidney unit, now Carlyle-owned (private equity), on the products side.[29]
• Value-based kidney-care companies — Interwell Health (physician-centric, associated with Fresenius), Strive Health, Somatus, Monogram Health, and payer-led integration by Optum/UnitedHealth.[24]

Real-estate route: dialysis clinics are long-lease, single-tenant medical buildings; net-lease REITs (real estate investment trusts) and private real-estate investors own the bricks without touching clinical risk.

Bottom line: for operating exposure in the public market, it is effectively DVA or FMS. Everything else is a supplier, a real-estate play, or a private stake — and a complete current cap table of private owners is not publicly available.

5. How the money works

Owners make money one treatment at a time. The core unit metrics are revenue per treatment, treatments per clinic (station utilization), and cost per treatment. A typical in-center patient dialyzes about three times a week — roughly 156 treatments a year — so a stable patient is an annuity. Patients may receive up to three hemodialysis treatments per week unless more is medically justified.[10]

The central economic fact is payer mix. There are two very different prices for the identical service:

• Medicare pays a single bundled rate per treatment under the ESRD Prospective Payment System (PPS): $273.82 in 2025, rising to $281.71 in 2026.[10][11] The bundle covers the treatment, supplies, lab work, drugs, and biologicals, with case-mix and facility adjustments (patient characteristics, wages, geography, rural status, facility size, home-training). CMS expects to pay about $6 billion to roughly 7,600 facilities in 2026.[10] This rate roughly covers cost or leaves a thin loss.
• Commercial (employer) insurance pays several times more. One peer-reviewed study found a for-profit chain collected about $1,041 per treatment from private insurers versus about $248 from the government — roughly 4x.[12]

Because Medicare (including Medicare Advantage) covers the large majority of patients and commercial insurance only about a tenth, that small commercial slice generates a disproportionate share of profit and effectively subsidizes the Medicare book. DaVita illustrates the split: in 2025 its U.S. dialysis patient-service revenue was 57% Medicare and Medicare Advantage, 7% Medicaid and managed Medicaid, 3% other government, and 32% commercial — i.e., roughly a third of revenue from roughly a tenth of patients (a company-specific figure, not an industry average).[1]

Providers earn the high commercial rate during a 30-month coordination period after a working-age patient qualifies for Medicare; after that window Medicare becomes primary and revenue per treatment for that patient drops sharply.[13] Protecting and extending that commercial window is the single biggest lever on margins — and the source of most of the industry's legal controversy (§7, §9).

Cost structure is largely fixed and labor-heavy: nurses, patient-care technicians, social workers, dietitians, and medical directors; the clinic, its stations, water-treatment systems, and maintenance; dialyzers, bloodlines, fluids, and drugs; plus lab, transport, billing, IT, and compliance. That makes the business a utilization game — profit rises as you pack more treatments through the same stations and staff, and falls when census dips. Watch treatment volume, same-center (non-acquired) growth, revenue per treatment, denial rates, and collections.

The newer margin lever is value-based care. Instead of billing per treatment, operators take risk-based contracts for the total cost of a kidney patient's care and keep a share of the savings (slowing disease, avoiding hospitalizations, steering to home dialysis and transplant). DaVita reported roughly 66,000 patients in integrated-care arrangements — about $5.6B of annualized medical spend — and its first profitable year in that segment in 2025.[1] Interwell Health, the largest participant in Medicare's value-based kidney model, reported $273M of shared savings over three years.[24]

6. What drives demand

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) reports more than 808,000 Americans living with ESKD, 68% on dialysis and 32% with a transplant.[9] Key drivers:

• Diabetes, high blood pressure, and aging. These are the leading causes of chronic kidney disease (CKD) and kidney failure; obesity and demographics feed the pipeline. This is the structural tailwind.[9]
• Medicare coverage. Since 1972, federal law has covered anyone with permanent kidney failure regardless of age — the only disease-specific Medicare entitlement — which underwrites near-universal demand.
• Incidence has been flattening to declining. ESRD prevalence dipped after 2020, driven mostly by fewer in-center hemodialysis patients, while home dialysis and transplant kept rising; COVID-era excess mortality among dialysis patients also cut census.[9]
• The GLP-1 / SGLT2 disruption. A newer class of drugs (GLP-1 agonists and SGLT2, sodium-glucose co-transporter-2, inhibitors) slows kidney disease. In the FLOW trial, semaglutide cut major kidney events by 24% in diabetic CKD patients, and the FDA expanded the label in 2025 to include kidney-risk reduction.[15] Over time this is a genuine, if slow-moving, headwind to how many people reach dialysis — and a reason the industry is pushing into value-based care and home modalities.
• Home dialysis. About 15% of U.S. dialysis patients were treated at home in 2025 (Fresenius, consistent with U.S. Renal Data System figures); the rest dialyze in-center.[2] Home PD is the fastest-growing modality and a policy priority — it can reduce in-center chair demand while creating training, supply, and equipment revenue.
• Transplantation. A successful transplant removes a patient from dialysis (a clinical good, a volume negative), but limited organ supply keeps dialysis the continuing treatment for most patients.

Editorial judgment: demand is durable but no longer reliably growing in unit terms. The forward story is less "more chairs" and more revenue per patient, home shift, and value-based savings.

7. Regulation

Dialysis is one of the most regulated corners of U.S. health care because Medicare and Medicaid are the dominant payers.

• Federal certification. Medicare-certified facilities must meet ESRD Conditions for Coverage under 42 Code of Federal Regulations (CFR) Part 494. CMS and state survey agencies monitor staffing, patient rights, infection control, water quality, care plans, emergency preparedness, and quality improvement.[16]
• CMS price-setting. CMS updates the ESRD PPS bundled base rate annually through rulemaking ($281.71 for 2026), using a market-basket and productivity methodology plus adjustments. An update that lags wage and drug inflation is a real-terms cut.[10]
• Quality Incentive Program (ESRD QIP). CMS publicly reports facility performance and can cut Medicare payments (up to 2%) for facilities that miss benchmarks.[17]
• Drugs into the bundle. Injectable anemia drugs were folded into the 2011 bundle; from January 1, 2025, oral phosphate binders entered via a Transitional Drug Add-on Payment Adjustment (TDAPA) — paid on top of the base rate for at least two years before absorption.[31]
• Medicare Advantage access. Since the 21st Century Cures Act (effective 2021), ESRD patients can enroll in Medicare Advantage, shifting the mix toward managed-care plans that pay less than commercial but more than traditional Medicare.
• Commercial-rate law. In Marietta Memorial Hospital v. DaVita (2022) the Supreme Court ruled 7–2 that an employer plan may cap dialysis reimbursement so long as it does so uniformly — limiting providers' ability to force higher commercial payments and threatening the subsidy model.[14]
• Fraud and referral rules. The Anti-Kickback Statute, False Claims Act, and physician self-referral (Stark) rules create real exposure for improper financial relationships with nephrologists, hospitals, and referral sources — for example, DaVita's 2024 agreement to pay over $34 million to resolve kickback allegations.[20] Regulators and insurers have also scrutinized routing patients' commercial-plan premiums through charities such as the American Kidney Fund to keep them on higher-paying private insurance.[21]
• Value-based models. CMS's mandatory ESRD Treatment Choices (ETC) home-dialysis model ends December 31, 2025 after evaluations found no statistically significant effect; the voluntary Kidney Care Choices (KCC) model continues.[10][24]
• State entry rules. Certificate-of-Need (CON) laws vary by state; the National Conference of State Legislatures reported 35 states and the District of Columbia operating CON programs as of January 2025, some specifically regulating dialysis facilities or station additions — which can protect incumbents.[18]

8. Competitive dynamics and consolidation

This is a textbook duopoly. DaVita and Fresenius together operated 74% of U.S. dialysis facilities and 75% of stations in 2024, and the four-firm revenue share was 88.4% in 2022.[3][5] Barriers to entry are steep: scale purchasing of machines and drugs, CON laws in some states, the need for a joint venture with local nephrologists, and a Medicare bundle that rewards size. Yet competition remains intensely local — patients dialyze several times a week, so travel distance and physician relationships decide market share clinic by clinic.

Consolidation is decades old and largely complete at the top, and antitrust enforcement is now a practical constraint. In 2022 the Federal Trade Commission required DaVita to divest three Utah clinics and imposed a ten-year prior-approval requirement for future dialysis acquisitions in that state.[19] The remaining moves are at the edges: regional roll-ups, the PE-owned #3 (U.S. Renal Care), and vertical integration. Fresenius uniquely spans the whole stack — it makes the machines and dialyzers, runs the clinics, and owns a value-based-care arm (Interwell). DaVita is pushing down the same path with integrated kidney care, and payers like UnitedHealth/Optum are buying into nephrology. The competitive front is shifting from "who owns the clinic" to "who manages the total cost of the kidney patient." Meanwhile, net clinic closures rose from 2018 to 2024 as low-volume and rural sites came under pressure.[32]

Editorial judgment: further consolidation is likely in fragmented local markets, but the largest buyers will face more divestiture demands, ownership scrutiny, and limits on physician and employee arrangements.

9. Key risks

• Reimbursement dependence. Most revenue is a government-set price. A skinny annual bundle update, or any policy that narrows the commercial-rate premium, hits margins directly; Marietta and Medicare Advantage growth both point that way.[10][14]
• Commercial-mix erosion. The profit engine is roughly a tenth of patients. Insurer repricing, network narrowing, higher authorization/denial activity, and anti-steering enforcement all threaten it — as the American Renal / UnitedHealthcare $32M settlement showed.[21]
• Demand disruption. GLP-1/SGLT2 drugs slowing CKD progression, plus transplant growth, could gradually shrink the dialysis pipeline.[15]
• Home-dialysis shift. Improves outcomes and policy standing but can compress in-center station utilization if not managed.
• Labor. Nurse, technician, and nephrologist shortages and wage inflation raise the largest cost line and can cap capacity.
• Quality and compliance. Infection, mortality, missed-treatment, billing, kickback, or documentation failures can trigger penalties, litigation, or loss of certification.
• Litigation and antitrust. The industry faces chronic kickback and steering suits, FTC divestiture demands, and even a first-of-its-kind criminal no-poach prosecution of DaVita (acquitted, 2022) — legal overhang persists even when the companies win.[19][22]
• Operational resilience. Power failures, hurricanes, supply disruptions, and cyberattacks can interrupt a life-critical service — a 2025 ransomware attack on DaVita exposed data on about 2.7 million people and dented billing and volumes.[23]
• Leverage and ownership complexity. Big operators carry meaningful debt; PE leases, physician joint ventures, and nonconsolidated centers can obscure true cash economics, and rate cuts bite harder on a levered balance sheet.
• Single-payer / policy tail risk. Any move toward Medicare-for-all-style pricing would remove the commercial subsidy entirely.

10. How to invest, and the outlook

Public routes.

• DaVita (DVA) — the concentrated U.S. pure play: stable volumes, aggressive buybacks (Berkshire's ~45% stake rises in percentage terms as DaVita repurchases stock), and a value-based-care option now turning profitable.[1] The risk is that it is all U.S. dialysis, so U.S. reimbursement and commercial-mix policy are the whole thesis. Track U.S. patient and treatment growth, commercial-payer exposure, revenue per treatment, labor and supply cost, center-level margin, leverage, and capital spending.
• Fresenius Medical Care (FMS) — global and more diversified (clinics + devices + pharmaceuticals + value-based care), mid-turnaround with sharply higher 2025 earnings.[2] Owning the sector with less single-country policy risk means separating U.S. clinic performance from medical technology, pharmaceuticals, and foreign-exchange effects.
• For both, EBITDA (earnings before interest, taxes, depreciation, and amortization) and free cash flow matter, but should be reconciled to patient volume, station utilization, quality performance, and capital needs — not viewed in isolation.
• Suppliers / disruptors — Outset Medical (OM) on home dialysis; Baxter (BAX) on renal products; Amgen (AMGN) on drugs; Novo Nordisk / Eli Lilly (NVO / LLY) as a hedge on the "fewer future dialysis patients" thesis.[29][30][15]

Private routes. Operating equity in the #3–#5 chains (U.S. Renal Care, Innovative Renal Care) via PE vehicles; physician joint ventures at the clinic level; value-based-care companies (Strive, Somatus, Monogram, Interwell); and net-lease ownership of the clinic buildings — a bond-like income play divorced from clinical margin.[24][25][26] Underwrite local demand and competitor capacity, current station utilization and ramp time, the full payer contract set (Medicare, Medicaid, Medicare Advantage, commercial), physician-ownership and referral compliance, CON and licensing, staffing depth, deferred maintenance on water systems and machines, quality history and denials, and an exit valued on durable cash flow rather than raw center count.

Outlook (forward-looking judgment). The base case is a resilient, reimbursement-led, cash-generative sector defended by a duopoly moat — modest underlying growth, not a growth story. The best assets are centers with strong local physician relationships, high station utilization, reliable staffing, favorable payer mix, clean quality records, and room to expand home or value-based care. The main mistake is treating dialysis as a simple volume business; the durable edge is a combination of patient access, clinical execution, reimbursement expertise, compliance, and local density. Near-term items to watch: the 2026 bundle at $281.71 and whether future updates keep pace with inflation;[10] how phosphate binders and other drugs settle into the bundle;[31] the pace of the home-dialysis and Medicare-Advantage mix shifts; DaVita's recovery from the 2025 cyber incident;[23] and the maturing of value-based kidney care as the primary new profit lever.[24] The two swing factors that matter most for owners over the next several years are defense of the commercial-insurance premium and the long-run demand drag from GLP-1/SGLT2 drugs. Neither is fatal in the near term, but both cap how bullish an investor can reasonably be.

---

Sources

1. DaVita Inc., Form 10-K for the year ended December 31, 2025 (2026), SEC EDGAR. https://www.sec.gov/Archives/edgar/data/927066/000092706626000012/dva-20251231.htm
2. Fresenius Medical Care AG, Annual Report 2025 and Equity Story (2025–2026). https://freseniusmedicalcare.com/en/investors/equity-story/equity-story/
3. Medicare Payment Advisory Commission (MedPAC), March 2026 Report to the Congress: Medicare Payment Policy — outpatient dialysis chapter (2026). https://www.medpac.gov/wp-content/uploads/2026/03/Mar26_MedPAC_Report_To_Congress_SEC.pdf
4. U.S. Census Bureau, County Business Patterns 2023, NAICS 621492 (establishments, employment, payroll). Histometrics ingested federal statistics.
5. U.S. Census Bureau, 2022 Economic Census — Concentration by Largest Firms, NAICS 621492 (receipts, firms, CR4/CR8/CR20/CR50; HHI suppressed). Histometrics ingested federal statistics.
6. U.S. Small Business Administration, Table of Size Standards (2023), NAICS 621492 ($47M average annual receipts). Histometrics ingested federal statistics.
7. U.S. Census Bureau and Office of Management and Budget, 2022 NAICS Manual, NAICS 621492 and adjacent codes. https://www.census.gov/naics/reference_files_tools/2022_NAICS_Manual.pdf
8. U.S. Census Bureau, County Business Patterns Methodology (coverage/exclusions). https://www.census.gov/programs-surveys/cbp/technical-documentation/methodology.html
9. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Kidney Disease Statistics for the United States; U.S. Renal Data System (USRDS) 2024 Annual Data Report. https://www.niddk.nih.gov/health-information/health-statistics/kidney-disease
10. Centers for Medicare & Medicaid Services (CMS), Calendar Year 2026 ESRD PPS Final Rule — base rate $281.71; ~$6B to ~7,600 facilities; ETC model ends Dec 31, 2025 (2025). https://www.cms.gov/newsroom/fact-sheets/calendar-year-cy-2026-end-stage-renal-disease-esrd-prospective-payment-system-final-rule
11. CMS, Calendar Year 2025 ESRD PPS Final Rule (CMS-1805-F) — base rate $273.82 (2024). https://www.cms.gov/newsroom/fact-sheets/calendar-year-2025-end-stage-renal-disease-esrd-prospective-payment-system-pps-final-rule-cms-1805-f
12. Craig KJT et al., "A Comparison of Payments to a For-profit Dialysis Firm From Government and Commercial Insurers," JAMA Internal Medicine (2019) — ~$1,041 commercial vs ~$248 government per treatment. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2732689
13. Medicare Interactive / CMS, "The 30-Month Coordination Period for People with ESRD." https://www.medicareinteractive.org/understanding-medicare/health-coverage-options/medicare-and-end-stage-renal-disease-esrd/the-30-month-coordination-period-for-people-with-esrd
14. Marietta Memorial Hospital Employee Health Benefit Plan v. DaVita Inc., 596 U.S. ___ (2022), U.S. Supreme Court. https://www.supremecourt.gov/opinions/21pdf/20-1641_3314.pdf
15. American Diabetes Association / Diabetes Care, "FLOW Trial: Semaglutide reduces major kidney events by 24%"; FDA kidney-risk label expansion (2024–2025). https://diabetes.org/newsroom/press-releases/semaglutide-reduced-risk-major-kidney-disease-events-24-patients-type-2
16. CMS, End-Stage Renal Disease Conditions for Coverage (42 CFR Part 494). https://www.cms.gov/medicare/health-safety-standards/certification-compliance/end-stage-renal-disease
17. CMS, ESRD Quality Incentive Program: Public Reporting. https://www.cms.gov/medicare/quality/end-stage-renal-disease-esrd-quality-incentive-program/public-reporting-certificates
18. National Conference of State Legislatures, Certificate of Need State Laws — 35 states + D.C. as of January 2025. https://www.ncsl.org/health/certificate-of-need-state-laws
19. Federal Trade Commission, "FTC Approves Final Order Imposing Strict Limits on Future Mergers by Dialysis Service Provider DaVita" (2022) — Utah divestiture, 10-year prior approval. https://www.ftc.gov/news-events/news/press-releases/2022/01/ftc-approves-final-order-imposing-strict-limits-future-mergers-dialysis-service-provider-davita-inc
20. U.S. Department of Justice, "DaVita to Pay Over $34 Million to Resolve Allegations of Illegal Kickbacks" (2024). https://www.justice.gov/usao-co/pr/davita-pay-over-34m-resolve-allegations-illegal-kickbacks
21. Fierce Healthcare, "American Renal pays $32M to settle UnitedHealthcare premium-assistance/steering claims" (2018). https://www.fiercehealthcare.com/payer/american-renal-associates-unitedhealthcare-32m-settlement-premium-assistance
22. Fierce Healthcare / Law360, "Jury acquits DaVita, ex-CEO in criminal no-poach antitrust trial" (2022). https://www.fiercehealthcare.com/providers/antitrust-case-against-davita-ex-ceo-now-hands-jury-doj-faces-setback-texas-verdict
23. HIPAA Journal / Healthcare Dive, "DaVita confirms 2025 ransomware attack affecting ~2.7M individuals." https://www.hipaajournal.com/davita-ransomware-attack/
24. Interwell Health, "Strong Quality Scores and Shared Savings in CMS Value-Based Kidney Care Model" (2025); CMS Kidney Care Choices (KCC) model. https://www.prnewswire.com/news-releases/interwell-health-delivers-strong-quality-scores-and-shared-savings-in-cms-value-based-kidney-care-model-302796191.html
25. U.S. Renal Care, "About / Locations"; Bain Capital healthcare portfolio; U.S. Renal Care investor-group acquisition announcement (2019–2026). https://www.usrenalcare.com/about/
26. Innovative Renal Care, "About"; Business Wire, "American Renal Associates Completes Transaction With Innovative Renal Care, a Nautic Partners Portfolio Company" (2021). https://innovativerenal.com/professional/about/
27. Dialysis Clinic, Inc., "Our Story" (2025–2026). https://www.dciinc.org/about/story/
28. Satellite Healthcare, "About Us" (2026). https://careers.satellitehealth.com/global/en/about-us
29. Carlyle Group / Baxter International, "Baxter to Divest Vantive Kidney Care to Carlyle for $3.8 Billion" (2024–2025). https://www.carlyle.com/media-room/news-release-archive/baxter-announces-definitive-agreement-divest-its-vantive-kidney
30. Outset Medical Inc., Form 10-K FY2025 (2026), SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1484612/000119312526051278/om-20251231.htm
31. CMS / McGuireWoods, "CMS Issues 2025 ESRD PPS Final Rule" — oral phosphate binders paid via TDAPA effective Jan 1, 2025. https://www.mcguirewoods.com/client-resources/alerts/2024/12/cms-issues-2025-end-stage-renal-disease-prospective-payment-system-final-rule/
32. ESRD Networks, "National ESRD Census Data" (2025); ScienceDirect, "Dialysis Facility Closures in the US, 2018–2024." https://esrdnetworks.org/resources-news/national-esrd-census-data/